A hyperacute immune map of ischaemic stroke patients reveals alterations to circulating innate and adaptive cells

S. Krishnan‡,*,†‡ C. O’Boyle ‡,†§ C. J. Smith ‡,*,†‡ S. Hulme ‡,†§ S. M. Allan ‡,*,†‡ J. R. Grainger ‡,†‡,1 and C. B. Lawrence ‡,*,†§,1

*Geoffrey Jefferson Brain Research Centre, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, †Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, ‡Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, §Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, and **Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK

Accepted for publication 9 November 2020
Correspondence: S. Krishnan and J. R. Grainger and C. B. Lawrence, Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester M13 9PT, UK.
E-mail: siddharth.krishnan@manchester.ac.uk and john.grainger-2@manchester.ac.uk and catherine.lawrence@manchester.ac.uk
1Joint senior authors.

Summary

Systemic immune changes following ischaemic stroke are associated with increased susceptibility to infection and poor patient outcome due to their role in exacerbating the ischaemic injury and long-term disability. Alterations to the abundance or function of almost all components of the immune system post-stroke have been identified, including lymphocytes, monocytes and granulocytes. However, subsequent infections have often confounded the identification of stroke-specific effects. Global understanding of very early changes to systemic immunity is critical to identify immune targets to improve clinical outcome. To this end, we performed a small, prospective, observational study in stroke patients with immunophenotyping at a hyperacute time point (< 3 h) to explore early changes to circulating immune cells. We report, for the first time, decreased frequencies of type 1 conventional dendritic cells (cDC1), haematopoietic stem and progenitor cells (HSPCs), unswitched memory B cells and terminally differentiated effector memory T cells re-expressing CD45RA (TEMRA). We also observed concomitant alterations to human leucocyte antigen D-related (HLA-DR), CD64 and CD14 expression in distinct myeloid subsets and a rapid activation of CD4+ T cells based on CD69 expression. The CD69+CD4+ T cell phenotype inversely correlated with stroke severity and was associated with naive and central memory T (TCM) cells. Our findings highlight early changes in both the innate and adaptive immune compartments for further investigation as they could have implications the development of post-stroke infection and poorer patient outcomes.

Keywords: clinical study, ischaemic stroke, neuroimmunology, stroke immunophenotypes, systemic immunity

Introduction

Stroke (cerebral ischaemia) is the leading cause of adult disability and a major cause of death worldwide [1,2]. In addition to initial neurological impairments, such as dysphagia, stroke can rapidly exacerbate the risk of bacterial pneumonia which is independently associated with increased mortality and worse functional outcome in survivors [3–6]. Bacterial pneumonia could, in part, result from a pneumonitis with an inflammatory component [7,8].
Together with reduced motor control (e.g. contralateral respiratory muscle/diaphragmatic weakness contributing to hypoventilation) [9] and increased vagal drive [10], treatment in a high infection risk environment could also exacerbate an environment for the development of bacterial pneumonia. The ineffectiveness of candidate primary interventions such as prophylactic β-blockers and antibiotic therapy in preventing stroke-associated pneumonia (SAP) has necessitated a clearer understanding of the systemic immune landscape in stroke, to identify mechanisms underlying early complications and new therapeutic approaches to improve patient outcome [11–13]. As most infections, particularly SAP, manifest within the first 72 h of stroke onset [14], novel strategies to prevent SAP need to be applied as soon as possible after stroke occurrence. Defining changes in the circulating immune cell compartment very early (within hours) after stroke onset, prior to manifestation of infections, is therefore critical.

Cerebral ischaemia drives local microglial activation in tandem with peripheral immune cell (e.g. monocytes, neutrophils, B cells and T cells) recruitment into the brain, as well as the production and release of cytokines and chemokines [15]. The ensuing inflammation is adversely involved in the evolution of stroke pathology and through its impact on systemic immunity leads to an increased risk of infection by impairing anti-microbial function. The mechanisms underlying systemic immune changes after stroke are not fully understood, but increased catecholamine release by the sympathetic nervous system, glucocorticoids and changes in cholinergic output are proposed [4,16–18].

There exists a wealth of literature implicating alterations to the abundance or functional capacity of almost all immune cells, including T cell subsets [19–25], B cells [26–28], invariant natural killer T (iNK T) cells [29], mononuclear phagocytes [30–33] and neutrophils [34–36] following acute ischaemic stroke. Commonly reported immunophenotypes are lymphopenia [37], elevated neutrophil–lymphocyte ratios [38,39], decreased human leucocyte antigen D-related (HLA-DR) expression on monocytes [31,32] and hypogammaglobulinaemia [26,40], as well as impaired production of reactive oxygen species by neutrophils [34,36]. In many of these studies, alterations to individual populations or specific arms of the immune system (i.e. innate or adaptive) were characterized and a more global immunophenotyping approach was not taken. Moreover, acute changes to systemic immunity have typically been characterized within 12 or 24 h of disease onset [3,29,34,41–44]. To date, the earliest point at which alterations to immunity have been documented is 3 h following stroke onset, predominantly focusing upon monocytes, their phenotype and relationship with clinical outcome [37]. Thus, the characteristic changes exhibited between myeloid and lymphoid immune populations following ischaemic stroke have not been concurrently documented in the same patient cohort in the hyperacute (< 3 h) phase.

To this end, we performed a small, prospective, observational immunophenotyping study where we explored the profile of forty immune parameters across three panels on whole blood cells from ischaemic stroke patients at a median time of 168 min following stroke symptom onset and in controls of similar age and sex distribution. Our data identify for the first-time decreased frequencies of a specific subset of dendritic cells (DC) (type I conventional dendritic cells, cDC1), altered expression of HLA-DR, CD64 and CD14 in distinct myeloid populations and alterations to haematopoietic stem and progenitor cells (HSPC). We also show a previously undescribed modulation of memory B cells as well as terminally differentiated effector memory T cells re-expressing CD45RA (TEMRA). Based on CD69 expression, we also observed a rapid activation of naive and central memory T (TCM) CD4+ T cells, the latter of which are capable of migration to lymphoid organs and orchestrate antigen recall responses [45]. The frequency of CD69+CD4+ T cells inversely correlated with stroke severity. Our findings highlight unappreciated early changes in both the innate and adaptive immune compartments to be validated in larger cohorts of patients, and provide valuable hypothesis generation regarding how diverse immune cell populations could independently and differentially change following stroke.

Materials and methods

Participants, study design and sample acquisition

Samples in this study were part of the flow cytometry substudy and obtained from participants recruited as part of the Subcutaneous Interleukin-1 Receptor Antagonist (IL-1Ra) in Stroke Study [46]. This was a Phase II clinical trial conducted at Salford Royal NHS Foundation Trust (SRFT) and received ethical approval from the Greater Manchester South NHS Research Ethics Committee, UK Medicines and Healthcare Products Regulatory Agency (MHRA) and SRFT Research and Development (Ethics ref.: 13/NW/0460; EudraCT no: 2013-001757-28; Sponsor Ref no.: 2013/066st). In brief, patients aged over 18 years with a diagnosis of ischaemic stroke < 5 h of symptom onset presenting at the Manchester Centre for Clinical Neurosciences (MCCN) Hyper Acute Stroke Unit (HASU) were recruited as previously described [46]. Approval was obtained to draw a blood sample immediately on admission (median time to sample was 168 min), prior to thrombolysis (when eligible), randomization to treatment and receipt of consent for participation in the Phase II trial. The National
Institutes of Health Stroke Scale (NIHSS) was used to assess stroke severity at admission; investigational treatment was administered < 6 h within symptom onset. Community-dwelling control participants with similar age and sex distribution to the patients and with no prior history of transient ischaemic attack or stroke, or infection treated with antibiotics within the preceding 6 weeks and capable of informed consent were also recruited. The demographics and baseline characteristics of the cohort are summarized in Table 1.

**Cell isolation from blood**

Briefly, 3 ml of venous blood collected in ethylenediamine tetraacetic acid (EDTA) tubes (Sarstedt, Leicester, UK) was washed in phosphate-buffered saline (PBS) and resuspended in 9 ml of sterile water (Hyclone, Cramlington, UK) for 10 sec at room temperature twice. Cell suspensions were washed, resuspended in PBS and counted before staining.

**Flow cytometry**

Single-cell suspensions of blood (~3 × 10^6–5 × 10^6 total cells) were incubated in PBS for 15 min at 4°C in the dark with the Zombie UV™ or Zombie Aqua™ Fixable Viability Kit (BioLegend, London, UK) as appropriate and immunoglobulin (Ig)G from human serum (Sigma Aldrich, Gillingham, UK). Cells were washed in PBS and stained for a further 15 min in three cocktails of fluorochrome-conjugated antibodies to identify myeloid, B or T cell subsets. Our immunophenotyping panels were adapted from Haniffa et al. [47], Tsang et al. [48], Thome et al. [49] and Thome et al. [50], which are summarized in Table 2. Cells were fixed in 2% paraformaldehyde (Sigma Aldrich) at room temperature for 10 min, washed and resuspended in PBS prior to acquisition. Samples were acquired on an LSR Fortessa using facsdiva version 8 software (BD Biosciences) and, typically, all cells in the sample were collected. Data were analysed using FlowJo software (Treestar, Inc., Ashland, OR, USA).

We identified all immune cells based on their expression of CD45 and the lineages were determined based on the indicated markers:

**Myeloid cells.** Myeloid cells were as follows: neutrophils: SSC^b^CD66b^CD16^; basophils: SSC^b^CD123^; classical monocytes: Lin^−^CD3ε^−^CD19^−^CD20^−^CD15^−^CD56^−^CD66b^−^HLA-DR^−^CD14^+^CD16^−^; intermediate monocytes: Lin^−^HLA-DR^−^CD14^+^CD16^−^non-classicalmonocytesLin^−^HLA-DR^−^CD14^+^CD16^−^; conventional DC1: Lin^−^HLA-DR^+^CD14^+^CD16^+^CCR2^+^CD141^+^; conventional DC2: Lin^−^HLA-DR^+^CD14^+^CD16^−^CCR2^−^CD1c^−^; plasmacytoid DC: Lin^−^HLA-DR^+^CD14^+^CD16^+^CCR2^+^CD123^+^; and haematopoietic stem and progenitor cells: Lin^−^CD3ε^−^CD19^−^CD20^−^CD15^−^CD56^−^CD66b^−^HLA-DR^−^CD123^−^CD14^−^CD16^−^CD11c^−^CD64^−^CD34^−^.

**B cells.** B cells were as follows: CD3ε^−^CD19^+^CD20^+^; plasmablasts: (B cells) CD27^{high}CD38^{high}; unswitched memory: (B cells) CD27^{low}CD38^{low}; switched memory: (B cells) CD27^{low}CD38^{high}; naive: (B cells) CD27^{low}CD38^{low}; and double-negative (B cells) CD27^{low}CD38^{low}.

---

**Table 1. Summary demographics of sampled population**

|                        | Control (15) | Stroke (13) |
|------------------------|--------------|-------------|
| Age (years)            | 70 (65–76)   | 75 (65–81)  |
| Sex                     |              |             |
| Male                   | 9 (60%)      | 8 (61-5%)   |
| Female                 | 6 (40%)      | 5 (38-5%)   |
| Co-morbidities         |              |             |
| Smoking                |              |             |
| Smoker                 | 0/15 (0%)    | 3/11 (27-3%)|
| Ex-smoker              | 6/15 (40%)   | 2/11 (18-2%)|
| Non-smoker             | 9/15 (60%)   | 6/11 (54-5%)|
| Diabetes               | 5/14 (35-7%) | 2/12 (16-7%)|
| Hypertension           | 7/14 (50%)   | 5/12 (41-7%)|
| PVD                    | 5/14 (35-7%) | 0/11 (0%)   |
| CAD                    | 0/14 (0%)    | 3/12 (25%)  |
| AF                     | 0/14 (0%)    | 1/11 (9-1%) |
| COPD                   | 0/14 (0%)    | 1/10 (10%)  |
| Previous stroke/TIA    | 0/14 (0%)    | 3/13 (23-1%)|
| Stroke severity (NIHSS)|              |             |
| Mild (0–4)             | –            | 1/13 (7-7%) |
| Moderate (5–15)        | –            | 7/13 (53-8%)|
| Severe (> 16)          | –            | 5/13 (38-5%)|
| Thrombolysis           | –            | 11/13 (84-6%)|
| Infection              |              |             |
| At sample/admission    | 0/15         | 1/13 (7-7%) |
| Post stroke            | –            | 4/13 (30-8%)|
| Pneumonia              | –            | 3/13 (23-1%)|
| UTI                    | –            | 1/13 (7-7%) |
| Acute phase response   |              |             |
| CRP                    | –            | 2-21 (0-55–9-84) |
| IL-6                   | –            | 6-56 (0-58–8-07) |
| vWF                    | –            | 1-14 (0-97–2-55) |
| Differential whole      |              |             |
| blood counts           |              |             |
| WBC                    | –            | 7-60 (6-35–8-75) |
| Lymphocytes            | –            | 1-60 (1-35–2-10) |
| Neutrophils            | –            | 4-60 (3-60–6-15) |
| Monocytes              | –            | 0-40 (0-40–6-05) |
| Eosinophils            | –            | 0-20 (0-10–0-30) |
| Basophils              | –            | 0-10 (0-05–0-10) |
| Neutrophil–lymphocyte ratio | – | 2-75 (2-12–3-96) |

Data are median (interquartile range)^m where ^m is the number of missing data points.

n/N (%), where N is the total number of observations with available data.

AF = atrial fibrillation; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; TIA = transient ischaemic attack; PVD = peripheral vascular disease; NIHSS = National Institutes of Health Stroke Scale; UTI = urinary tract infection; CRP = C-reactive protein; IL-6 = interleukin-6; vWF = von Willebrand factor; WBC = white blood cells.
T cells. T cells were as follows: CD45$^+$CD3$^+$; γδ T cells: (T cells) T cell receptor (TCR)-γδ$^+$; CD4$^+$ T cells: (T cells) TCR-γδ$^-$CD4$^+$; CD8$^+$ T cells: (T cells) TCR-γδ$^-$CD8$^+$; among CD4 and CD8 T cells, we identified TEM: CCR7$^-$CD45RA$^-$; TCM: CCR7$^+$CD45RA$^-$; naive: CCR7$^+$CD45RA$^+$; and TEMRA: CCR7$^-$CD45RA$^+$.

**Dimensional reduction of flow cytometry data.** Flow cytometry data were gated to exclude debris, dead cells and doublets leaving behind live cells for Boolean gating and high-dimensional analyses. We employed a combination of expert guided manual gating and dimensional reduction using the uniform manifold approximation and projection (UMAP) algorithm, which we implemented in FlowJo. We adopted UMAP over t-distributed stochastic neighbor embedding (t-SNE), as it faithfully visualizes cell clusters in the high-dimensional space following dimensional reduction with a shorter run time [51,52]. UMAP plots were generated separately for individual samples, such that either the same number of cells or all available cells were sampled to avoid artefacts due to insufficient representation of cells in the sampled gate. Immune cells manually identified based on previously described characteristics were projected on the UMAP to generate a global immune map.

**Statistical analyses**

Statistical analyses were performed using Prism version 7/8 software (GraphPad, San Diego, CA, USA) and data are presented as median with individual data points. Statistical comparisons were performed using a Mann–Whitney U-test and correlations using Spearman's ranked coefficient correlation test. Following sample processing, surface staining and data acquisition, if insufficient cells were present in individual samples for specific panels they were excluded from analyses and appropriate sample numbers are indicated in the Figure legends. One control and stroke patient were excluded from all analyses as indicated in the results and a further three controls and two stroke patients lacked data for up to two panels.

**Results**

**Study cohort**

We established a research protocol to rapidly sample peripheral blood from ischaemic stroke patients upon admission to the HASU at the MCCN for deep immune profiling as well as assaying acute-phase proteins. In total, we recruited 13 patients who were stratified for stroke severity according to the NIHSS, of which we analysed 12 samples. We also recruited 16 control participants of similar age and sex distribution in our study (Table 1),

| Table 2. Staining panels used in immunophenotyping stroke patients |
|---------------------------------------------------------------|
| **Colour** | **Antibody** | **Clone** | **Supplier** |
| Myeloid panel |
| FITC | CD3 | UCHT1 | Biolegend |
| FITC | CD19 | HIB19 | Biolegend |
| FITC | CD20 | 2H7 | Biolegend |
| FITC | CD56 | MEM-188 | Biolegend |
| FITC | CD66b | G10F5 | Biolegend |
| FITC | CD15 | W6D3 | Biolegend |
| PerCP-Cy5.5 | CX3CR1 | 2A9-1 | Biolegend |
| APC | CD11c | B-ly6 | BD Pharmingen |
| AF700 | CD14 | M5E2 | Biolegend |
| APC-Cy7 | CD16 | 3G8 | Biolegend |
| BV421 | CD192 | K036C2 | Biolegend |
| (CCR2) |
| BV510 | Zombie Aqua | | |
| BV605 | CD34 | 581 | Biolegend |
| BV650 | HLA-DR | L243 | Biolegend |
| BV785 | CD123 | 6H6 | Biolegend |
| PE | CD141 | AD5-14H12 | Miltenyi Biotec |
| (BDCA-3) |
| PE-Cy7 | CD1c | L61 | Biolegend |
| PE-Dazzle™ 594 | CD64 | 10.1 | Biolegend |
| BUV395 | CD45 | HI30 | BD Biosciences |
| B cell panel |
| FITC | CD3 | UCHT1 | Biolegend |
| PerCP-Cy5.5 | CD23 | EBVCS-5 | Biolegend |
| APC | CD27 | M-T271 | Biolegend |
| AF700 | CD20 | 2H7 | Biolegend |
| APC-Cy7 | IgM | MHM-88 | Biolegend |
| BV421 | IgD | IA6-2 | Biolegend |
| BV510 | Zombie Aqua | | |
| BV650 | CD38 | HB-7 | Biolegend |
| BV711 | CD19 | HIB19 | Biolegend |
| PE | CD10 | H10a | Biolegend |
| PE-Cy7 | CD1c | L61 | Biolegend |
| PE-Dazzle™ 594 | CD45R | RA3-6B2 | Biolegend |
| T cell panel |
| FITC | V62 | B6 | Biolegend |
| PerCP-Cy5.5 | CD4 | OKT4 | Biolegend |
| APC | CD69 | FN50 | Biolegend |
| AF700 | CD3 | UCHT1 | Biolegend |
| APC-Cy7 | CCR7 | G043H7 | Biolegend |
| BV421 | FoxP3 | 206D | Biolegend |
| BV510 | CD25 | M-A251 | Biolegend |
| BV605 | CD45RA | H100 | Biolegend |
| BV650 | CD8 | SK1 | Biolegend |
| BV711 | CD45 | H100 | Biolegend |
| BV785 | CD127 | A019D5 | Biolegend |
| UV | Zombie UV | | |
| PE | PD1 | EH12.2H7 | Biolegend |
| PE-CF594 | TCRγδ | B1 | Biolegend |

FITC = fluorescein isothiocyanate; PerCp-Cy5.5 = peridinin chlorophyll-cyanin 5.5; APC = allophycocyanin; PE = phycoerythrin; TCR = T cell receptor; PD1 = programmed cell death 1; FoxP3 = forkhead box protein 3; Ig = immunoglobulin; HLA-DR = human leucocyte antigen D-related; AF700 = Alexa Fluor 700; BV = brilliant violet.
of which we analysed 15 samples. One control was excluded from all analyses due to a previous diagnosis of chronic lymphoid leukaemia, while one stroke patient was excluded, as sample processing yielded no viable cells for analysis. Our cohort of stroke patients was 62% male, with a median age of 75 [interquartile range (IQR) = 65–81] years whose characteristics are summarized in Table 1. The median time to blood sampling following stroke symptom onset was 168 min, at which point 85% of the patients were also thrombolysed after blood draw was obtained.

**Stroke alters the composition and phenotype of circulating myeloid cells in the hyperacute phase**

To characterize the heterogeneity of myeloid cells, we gated them to identify granulocyte, monocyte and dendritic cell subsets using well-established markers [53–55] (Supporting information, Fig. S1a). We identified all DCs based on their expression of CCR2 (Supporting information, Fig. S2a) and divided them into functionally distinct populations based on surface marker expression, notably types 1 and 2 conventional DC (cDC1 and cDC2) and plasmacytoid DC (pDC) [47,56]. The quantification of manually gated populations revealed a modest decrease in the frequency of cDC1s (Fig. 1a,b), while the frequencies of other myeloid populations remained unaltered (Supporting information, Fig. S2b–d). The frequencies of cDC1s post-stroke, however, did not correlate with the severity of stroke (Supporting Information, Fig. S2e). Enumerating the numbers of immune populations revealed a modest increase in monocytes, particularly classical monocytes (Fig. 1c). We also identified HSPCs based on CD34 expression and the lack of canonical lineage markers and observed a modest decrease in the frequencies of CD34+ HSPCs (Fig. 1D and Supporting information, Fig. S1b) that could be suggestive of alterations in haematopoietic output or potential.

Alterations to the surface phenotype myeloid populations have been linked to impairments in the ability to generate appropriate immune responses following infection. For example, the expression of HLA-DR has been shown to be critical for presenting processed antigens across a variety of cell lineages [57–59], while the FcγR has been shown to be indispensable for antigen uptake by cDC2s [60,61]. Therefore, we next investigated the surface phenotype of myeloid cells which highlighted HLA-DR, CD64 and CD14 as markers that were altered hyperacutely (Fig. 1e–g). Indeed, we identified a modest down-regulation of HLA-DR on intermediate monocytes, cDC2s and pDCs post-stroke, correlating with age but not stroke severity for cDC2s (Fig. 1e and Supporting Information, S2f). We also observed a significant down-regulation of CD64 (FcγRI; high-affinity Fc receptor for monomeric IgG) on classical monocytes and cDC2s (Fig. 1f). Furthermore, we identified increased CD14 (Toll-like receptor 4 signalling co-receptor) expression across all monocyte subsets (Fig. 1g). CD14 up-regulation has been linked to the acquisition of a tolerance to endotoxin challenge [62]. Taken together, our data could imply rapid alterations in antigen presentation, phagocytic capacity and the ability to secrete cytokines in response to infections following ischaemic stroke.

**Stroke rapidly decreases the frequency of unswitched memory B cells in circulation**

Stroke has been shown to drive the loss of B cells in experimental stroke [26], and they have been linked to cognitive decline post-stroke due to their recruitment to the ischaemic brain in patients [27]. To understand the early impact of cerebral ischaemia on B cells, we identified B cells in whole blood of stroke patients and observed that at a hyperacute time-point, frequencies of B cells were largely unaltered (Fig. 2a). Emerging research has highlighted impairments in antibody-mediated immunity as a key driver of post-stroke infections and the critical role that B cell subsets play [26,40,63]. We next identified memory B cell subsets based on their expression of IgD and CD27 [48], which revealed a decrease in the frequency of unswitched memory B cells (Fig. 2b), but this did not correlate with the stroke severity (Fig. 2c). Although plasmablasts and other memory B cell populations remained unaffected (Fig. 2b), a larger cohort might be required to identify changes to the pool of memory B cells. Given that unswitched B cells can rapidly mount IgM-driven anti-microbial responses and enter the germinal centre reaction [64–67], our observations suggest that stroke rapidly drives deficiencies in humoral immunity that could modulate infection susceptibility in patients.

**Stroke rapidly alters the phenotype of the memory T cell compartment in circulation**

Clinical studies have identified the loss of T cells in circulation [25,68,69] as well as long-term functional alterations [20] as a characteristic of stroke-induced immunosuppression. We first identified CD3ε+ T cells in the peripheral blood of controls and stroke patients. In accordance with previous studies, we identified a decrease in the frequency of T cells, but this did not correlate with stroke severity (Fig. 3a). Due to the segregation of functions between TCR-αβ+ and TCR-γδ+ T cells and their subsets [70–72], as well as the role of IL-17+ γδ T cells in exacerbating ischaemic injury [22,73], we characterized T cell subsets based on TCR as well as CD4 and CD8 expression. However, stroke did not impact the frequencies of CD4, CD8 or TCR-γδ+ T cell subsets at a hyperacute time-point (Supporting information, Fig. S3a).

To investigate the activation and exhaustion characteristics acquired by T cell subsets following stroke, we implemented the UMAP algorithm [51,52] on CD4+ and
CD8+ T cells and projected memory T cell subsets identified by their expression of CCR7 and CD45RA [49] on the dimensional reduction, and observed a decrease in TEMRA cells among CD4+ but not CD8+ cells (Fig. 3b and Supporting information, S3b). However, we observed a high degree of variability in the frequencies of memory CD8+ T cell subsets amongst patients, potentially ascribed to co-morbidities that were not matched with controls (Supporting information, Fig. S3b). Both the CD4+ and CD8+ compartments were rapidly activated by stroke, evidenced by the increased proportion of cells expressing CD69 (Fig. 3c–f), a marker of early T cell activation [74]. Increased frequencies of CD69+ T cells inversely correlated with stroke severity only in the CD4+ compartment (Fig. 3d). The increase in CD69+CD4+ cells was restricted to naive and central memory T cells (TCM), which also inversely correlated with stroke severity (Fig. 3e and Supporting information, S3c), while all memory subsets up-regulated CD69 in the CD8+ compartment (Fig. 3g). Finally, examining programmed cell death (PD)-1+ T cells within the CD4+ and CD8+ compartments as a measure of T cell exhaustion [75,76]...
revealed no alterations in PD-1+ cells within either compartment at a hyperacute time point (Fig. 3h).

Combined, our data outline how stroke swiftly alters the composition and phenotype of myeloid and lymphoid cells in circulation and could have implications for antigen presentation and circuits of humoral immunity as well as memory T cell responses.

Discussion

Infectious complications following ischaemic stroke present a significant barrier to recovery and are thought to be driven by alterations to the systemic immune landscape. Here, we present a hyperacute map of circulating immune cells in ischaemic stroke patients where we show decreased frequencies of cDC1s, HSPCs, unswitched memory B cells and TEMRA cells. We also identify concomitant alterations in the expression of HLA-DR, CD64 and CD14 in distinct myeloid subsets and a rapid activation of CD4+ T cells based on CD69 expression. Interestingly, this CD69+CD4+ T cell phenotype inversely correlated with stroke severity and was associated with naive and TCM cells.

The vast majority of CD4+ or CD8+ T cells have been shown to be CD69− in circulation [77] and the up-regulation of CD69 is thought to be a marker of early T cell activation, probably in response to the cytokine milieu and TCR engagement, which regulates cytokine production [74]. Although we observe an activation of T cell subsets post-stroke, the pathways driving their activation remain to be determined. Similarly, while we also implicate CD4+ TEMRA cells in the hyperacute immune response following stroke, further studies in larger patient cohorts are essential to determine their functional consequence and temporality, particularly in the context of long-term cognitive decline, as increased CD8+ TEMRA cells in circulation have been recently identified as an immunophenotype in patients with mild cognitive impairment or Alzheimer’s disease [78]. Given that TEMRA cells possess the capacity to migrate to peripheral tissues and take up residence [79], mechanistic studies are critical to determine whether the decreased frequencies observed could be attributed to their migration or loss via cell death. Studies have documented increased CD69+ T cells in the palatine tonsils and cervical lymph nodes of stroke patients 76 h following...
A hyperacute immune map of stroke patients

© 2020 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology, Clinical and Experimental Immunology, 203: 458–471
stroke onset [80], and that activated T cells reactive to myelin oligodendrocyte glycoprotein accumulate in the brain following experimental stroke [81,82]. Conversely, an exhausted T cell phenotype characterized by an increased frequency of PD-1+CD4+ T cells has also been observed in patients 48 h post-stroke [83]. Given the diverse T cell phenotypes and their pleiotropic roles post-stroke, it becomes crucial to dissect mechanisms that control immunoregulatory programmes in T cells balancing the requirement for a tightly regulated anti-microbial immune response versus initiating an autoimmune reaction.

Our observations concur with previously reported features of the disease and, by sampling patients soon after stroke onset, illustrate the rapid effects of stroke on systemic immunity. As such, alterations to the abundance of monocytes as well as their HLA-DR expression have been widely reported [31,69,84,85]; however, we demonstrate that it occurs within 3 h of symptom onset. Our study also highlights that the down-regulation of HLA-DR is a wider phenomenon, affecting cDC2s and pDCs that play key roles in priming T cell responses and type I interferon production. While myeloid DC precursors have previously been shown to be decreased in circulation following ischaemic stroke [33], recent years our understanding of DC biology and their associated subsets has grown [86–88]. Consequently, specific subsets that have been recently identified have not been investigated. In this context, our data outline phenotypical alterations to cDC1s, cDC2s and pDCs in the hyperacute phase post-stroke. Our data add to mounting evidence that implicate pDCs in the ensuing immune response post-stroke and illustrate that pDCs could acquire a functionally altered state within hours of stroke, in addition to their role in the sustained immune response post-stroke [13]. Further, the modest decrease in cDC1 frequencies we observe soon after stroke could result from their recruitment to the ischaemic brain, where they could prime detrimental T cell responses. However, only cDC2s (human: CD1c+, mouse: CD172a+) have been detected in the brain using post-mortem brain tissue and following experimental stroke [33,73]. Regardless, DCs have been shown to be reduced in circulation and exhibit an impaired capacity to secrete cytokines in patients following subarachnoid haemorrhage, a condition that also drives systemic immunosuppression [89]. Emerging evidence has also highlighted the existence of a novel inflammatory subset of cDC2s which are CD5−CD163+CD14+ and has implicated their expansion in systemic lupus erythematosus [90]. Given that we implicate stroke in modulating HLA-DR expression on cDC2s, it remains to be determined whether this phenotype could be ascribed to the newly described inflammatory cDC2 subset.

Altered monocyte phenotypes have previously been reported in stroke patients [30–32,84,91] and, congruent with previous data, we also identify a decreased expression of HLA-DR on intermediate monocytes. Although we report no alterations to monocyte proportions in the hyperacute phase of stroke, unlike previous data [31], our sample size and the observed variability could limit our ability to detect these phenotypes. Nevertheless, we identify novel alterations to the expression of CD64 on classical monocytes and CD14 across all monocyte subsets. Enhanced CD14 expression on monocytes has been linked to the acquisition of a tolerance to endotoxin exposure, characterized by an inability to secrete proinflammatory cytokines [62], a phenotype observed in stroke [92]. However, it is unclear if the increased levels of CD14 on monocytes are driven by up-regulation or the generation and release of CD14high monocytes from the bone marrow, analogous to the concept of innate immune training [15,93,94]. Taken together with alterations to CD64 expression, these alterations could probably compromise the ability of patients to response to infectious challenges.

Examining the heterogeneity in immune cells also demonstrated a modest reduction the frequency of HSPCs as well as unswitched B cells in circulation. Studies have
shown that in experimental stroke there are alterations in bone marrow haematopoiesis that confers a myeloid bias to HSPCs at the expense of lymphopoiesis, affecting B cell development [17,95]. Equally, it is plausible that HSPCs could be retained in inflamed tissues such as the ischaemic brain as they circulate and undergo local haematopoiesis [96,97]. Thus, while we identify a decrease due to ischaemic brain as they circulate and undergo local haematopoiesis [96,97]. Thus, while we identify a decrease in the frequency of IgD⁺CD27⁺ unswitched memory B cells, it is unclear if alterations in HSPC frequencies could mediate the balance of memory B cell subsets as migration and entry into the germinal centre reaction could occur more rapidly. What is clear, however, is that stroke swiftly alters the dynamics of the circulating memory B cells and potentially humoral responses. Further studies are required to causally implicate the decreased frequencies of unswitched memory B cells in driving the observed hypogammaglobulinaemia post-stroke [40,63]. Moreover, it also remains to be determined if stroke directly modulates the frequency and developmental potential of circulating HSPCs.

Our study has several limitations, including a small sample size recruited from a single hospital which might not be representative of the wider population of stroke patients. Serial blood samples in the patients were not obtained for immunophenotyping, meaning that insights into the changes in immune phenotype beyond the hyperacute phase were not possible. Our control and stroke groups are also not precisely matched for co-morbidities and our data could over-estimate the effect of stroke on immune function. This is evidenced by recent work that highlighted how risk factors for cerebrovascular disease and their genetic susceptibility loci, e.g. hypertension, obesity, atherosclerosis and hyperlipidaemia, can modulate haematopoiesis and innate immunity [98]. As a result, larger appropriately powered, co-morbidity-matched cohorts assessing multiple immune parameters are critical to validate our findings and to determine the relationships with post-stroke infection and clinical outcomes. Our small sample size and low numbers of patients with infection limit speculation on immunophenotypes that could be predictive of infection, further reinforcing the need for larger studies. Although we profile immune cell subsets, we were unable to concurrently map the systemic cytokine, complement, autonamical and hypothalamic-pituitary adrenal axis response with a similar level of depth due to insufficient blood volumes. Thus, mechanistic studies are essential to determine the differential roles of the adrenergic, cholinergic and glucocorticoid pathways driving early and delayed alterations to immune function. Although we present a snapshot of hyperacute immune alterations, it is equally important to analyse the temporality of immune changes over the acute and post-acute phases and how they shape outcome following the ischaemic insult; for example, in the context of cognitive decline [13]. Regardless, our study is the first to place an equal emphasis on the innate and adaptive immune compartments and prospectively identifies novel immunophenotypes that track with disease severity during the hyperacute phase of stroke, and that warrant more detailed follow-up studies.

Acknowledgements

This study was funded by grants from the Dowager Countess Eleanor Peel Trust and Medical Research Council (MR/K501311/1) to C. B. L., the President's Doctoral Scholar Award from the University of Manchester to S. K. and a Senior Fellowship funded by The Kennedy Trust for Rheumatology Research, Sir Henry Dale Fellowship funded by The Wellcome Trust and The Royal Society (104195/Z/14/Z) and a University of Manchester Institutional Strategic Support Fund Stepping Stones fellowship supported by The Wellcome Trust (grant 097820/Z/11/B) to J. R. G. We also acknowledge the Stroke IMPaCT Leducq Foundation (grant 19CVD001) award to S. M. A. and C. J. S. The SCIL-STROKE study was funded by the Stroke Association award (grant TSA 2012/08) to C. J. S. and S. M. A. We would like to acknowledge the support of the University of Manchester Flow Cytometry Core Facility. We would also like to thank the research nurses at Salford Royal NHS Foundation Trust for assistance with patient recruitment and sample collection. Special thanks to Dr Joanne Konkel, Amy Bradley and Hayley Bridgeman for technical assistance in the study.

Disclosures

The authors declare no competing interests.

Author contributions

S. H., S. M. A and C. J. S. set up the clinical protocol between UoM and SRFT. C. J. S. and S. H. co-ordinated the clinical study conduct and blood sampling. S. K., C. B. L., S. M.A and J. R. G. conceived and designed experiments. S. K. and C. O. performed experiments. S. K. analysed and interpreted data. S. K. wrote and reviewed the paper. All authors edited the paper, provided final approval and vouch for the contents of the final manuscript.

Data and Availability Statement

All data required to evaluate the conclusions presented in the paper are present in the paper or Supplementary Materials.
References

1 Feigin VL, Mensah GA, Norrving B et al. Atlas of the Global Burden of Stroke (1990–2013): the GBD 2013 study. Neuroepidemiology 2015; 45:230–6.

2 Norrving B, Davis SM, Feigin VL, et al. Stroke prevention worldwide – what could make it work. Neuroepidemiology 2015; 45:215–20.

3 Hug A, Dalpke A, Wieczorek N et al. Infarct volume is a major determinant of post-stroke immune cell function and susceptibility to infection. Stroke 2009; 40:3226–32.

4 Harms H, Reimnitz P, Bohner G, et al. Influence of stroke localization on autonomic activation, immunodepression, and post-stroke infection, Cerebrovasc Dis 2011; 32:552–60.

5 Shi K, Wood K, Shi F-D et al. Stroke-induced immunosuppression and poststroke infection. Stroke Vasc Neurol 2018; 3:34–41.

6 Vermeij FH, Scholte op Reimer WJM, de Man P, et al. Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey. Cerebrovasc Dis 2009; 27:465–71.

7 Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344:665–71.

8 Meisel A, Smith CJ. Prevention of stroke-associated pneumonia: where next? Lancet 2015; 386:1802–04.

9 Dubé B-P, Dres M. Diaphragm dysfunction: diagnostic approaches and management strategies. J Clin Med 2016; 5:113.

10 Engel O, Akyüz L, Di Costo Goncalves AC et al. Cholinergic pathway suppresses pulmonary innate immunity facilitating pneumonia after stroke. Stroke 2015; 46:3232–40.

11 Kalra L, Irshad S, Hodossal J et al. Prophylactic antibiotics after acute stroke for reducing pneumonia in patients with dysphagia (STROKE-INF): a prospective, cluster-randomised, open-label, masked endpoint, controlled clinical trial. Lancet 2015; 386:1835–44.

12 Maier IL, Becker JC, Leyhe JR et al. Influence of beta-blocker therapy on the risk of infections and death in patients at high risk for stroke induced immunodepression. PLOS ONE 2018; 13:e0196174.

13 Tsai AS, Berry K, Beneyto MM et al. A year-long immune profile of the systemic response in acute stroke survivors. Brain 2019; 142:978–91.

14 Kishore AK, Vail A, Chamorro A et al. How is pneumonia diagnosed in clinical stroke research? A systematic review and meta-analysis. Stroke 2015; 46:1202–9.

15 Krishnan S, Lawrence CB. Old dog new tricks; revisiting how stroke modulates the systemic immune landscape. Front Neurol 2019; 10:1–11.

16 Chamorro A, Amaro S, Vargas M et al. Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci 2007; 252:29–35.

17 Courties G, Froderrman V, Honold L, et al. Glucocorticoids regulate bone marrow B lymphopoiesis after stroke. Circ Res 2019; 124:1372–85.

18 Lafargue M, Xu L, Carlès M et al. Stroke-induced activation of the α7 nicotinic receptor increases Pseudomonas aeruginosa lung injury. FASEB J 2012; 26:2919–29.

19 Prass K, Meisel C, Höflich C et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003; 198:725–36.

20 Theodorou GL, Maroussi S, Ellul J et al. T helper 1 (Th1)/Th2 cytokine expression shift of peripheral blood CD4+ and CD8+ T cells in patients at the post-acute phase of stroke. Clin Exp Immunol 2008; 152:456–63.

21 Tuttolomondo A, Pecoraro R, Casuccio A et al. Peripheral frequency of CD4+ CD28− cells in acute ischemic stroke. Medicine 2015; 94:e813.

22 Benakis C, Brea D, Caballero S et al. Commensal microbiota affects ischemic stroke outcome by regulating intestinal γδ T cells. Nat Med 2016; 22:516–23.

23 Arunachalam P, Ludewig P, Melich P et al. CCR6 (CC chemokine receptor 6) is essential for the migration of detrimental natural interleukin-17–producing γδ T cells in stroke. Stroke 2017; 48:1957–65.

24 Singh V, Roth S, Llorella G et al. Microbiota dysbiosis controls the neuroinflammatory response after stroke. J Neurosci 2016; 36:7428–40.

25 Ruhnau J, Schulze J, von Sarnowski B et al. Reduced numbers and impaired function of regulatory T cells in peripheral blood of ischemic stroke patients. Mediat Inflamm 2016; 2016:1–9.

26 McCulloch L, Smith CJ, McColl BW. Adrenergic-mediated loss of splenic marginal zone B cells contributes to infection susceptibility after stroke. Nat Commun 2017; 8:15051.

27 Doyle KP, Quach LN, Sole M et al. B-lymphocyte-mediated delayed cognitive impairment following stroke. J Neurosci 2015; 35:2133–45.

28 McCulloch L, McCall BW, Allan SM et al. Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F21000Res 2019; 8:1039.

29 Wong CHY, Jenne CN, Tam PP et al. Prolonged activation of invariant natural killer T cells. J Exp Med 2016; 203:458–471.
A hyperacute immune map of stroke patients

34 Ruhnau J, Schulze K, Gaida B et al. Stroke alters respiratory burst in neutrophils and monocytes. Stroke 2014; 45:794–800.
35 Perez-de-Puig I, Miró-Mur F, Ferrer-Ferrer M et al. Neutrophil recruitment to the brain in mouse and human ischemic stroke. Acta Neuropathol 2014; 129:239–57.
36 Weisenburger-Lile D, Dong Y, Yger M et al. Harmful neutrophil subsets in patients with ischemic stroke. Neurol-Neuroimmunol Neuroinflamm 2019; 6:e571.
37 Uría X, Cervera A, Villamor N et al. Harms and benefits of lymphocyte subpopulations in patients with acute stroke. Neuroscience 2009; 158:1174–183.
38 Giede-Jeppe A, Madzar D, Sembill JA et al. Increased neutrophil-to-lymphocyte ratio is associated with unfavorable functional outcome in acute ischemic stroke. Neurocrit Care 2019; 33:97–104.
39 Nam K-W, Kim TJ, Lee JS et al. High neutrophil-to-lymphocyte ratio predicts stroke-associated pneumonia. Stroke 2018; 49:1886–92.
40 Liesz A, Roth S, Zorn M et al. Acquired immunoglobulin G deficiency in stroke patients and experimental brain ischemia. Exp Neurol 2015; 271:46–52.
41 Vogelgesang A, May VEL, Grunwald U et al. Functional status of peripheral blood T-cells in ischemic stroke patients. PLOS ONE 2010; 5:e8718.
42 Buck BH, Liebeskind DS, Saver JL et al. Early neutrophilia is associated with volume of ischemic tissue in acute stroke. Stroke 2008; 39:355–60.
43 O’Connell GC, Tennant CS, Lucke-Wold N et al. Monocyte–lymphocyte cross-communication via soluble CD163 directly links innate immune system activation and adaptive immune system suppression following ischemic stroke. Sci Rep 2017; 7:12940.
44 Chamorro Á, Amaro S, Vargas M et al. Interleukin 10, monocytes and increased risk of early infection in ischaemic stroke. J Neurol Neurosurg Psychiatry 2006; 77:1279–81.
45 Sallusto F, Lenig D, Förster R et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708–12.
46 Smith CJ, Hulme S, Vail A et al. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke). Stroke 2018; 49:1210–6.
47 Haniffa M, Shin A, Bigley V et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012; 37:60–73.
48 Tsang JS, Schwartzberg PL, Kotliarov Y et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 2014; 157:499–513.
49 Thome JJC, Bickham KL, Ohmura Y et al. Early-life compartmentalization of human T cell differentiation and regulatory function in mucosal and lymphoid tissues. Nat Med 2016; 22:72–7.
50 Thome JJC, Yudanin N, Ohmura Y et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell 2014; 159:814–28.
51 Becht E, McInnes I, Healy J et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol 2019; 37:38–47.
52 McInnes I, Healy J, Melville J. UMAP: Uniform manifold approximation and projection for dimension reduction. 2018. Available at: http://arxiv.org/abs/1802.03426 (accessed 10 July 2020).
53 Alcántara-Hernández M, Leytek R, Wagar LE et al. High-dimensional phenotypic mapping of human dendritic cells reveals interindividual variation and tissue specialization. Immunity 2017; 1037–50.
54 Hamers AAJ, Dinh HQ, Thomas GD et al. Human monocyte heterogeneity as revealed by high-dimensional mass cytometry. Arterioscler Thromb Vasc Biol 2019; 39:25–36.
55 Böttcher C, Fernández-Zapata C, Schlicker S et al. Multiparameter immune profiling of peripheral blood mononuclear cells by multiplexed single-cell mass cytometry in patients with early multiple sclerosis. Sci Rep 2019; 9:1–14.
56 Regev A, Teichmann SA, Lander ES et al. The Human Cell Atlas. Elife 2017; 6:e27041.
57 Farhan RK, Vickers MA, Ghaemmaghami AM et al. Effective antigen presentation to helper T cells by human eosinophils. Immunology 2016; 149:413–22.
58 Ferreira da Mota NV, Colo Brunialti MK, Santos SS et al. Immunophenotyping of monocytes during human sepsis shows impairment in antigen presentation: a shift toward nonclassical differentiation and upregulation of FcGRI-receptor. Shock 2018; 50:293–300.
59 Pinet V, Vergelli M, Martini R et al. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995; 375:603–6.
60 Lehmanna CHK, Baransa A, Heidkamp GF et al. DC subset-specific induction of T cell responses upon antigen uptake via Fcγ receptors in vivo. J Exp Med 2017; 214:1509–28.
61 Bosteels C, Nuyt K, Vanheerswynghels M et al. Inflammatory type 2 cDCs acquire features of cDC1s and macrophages to orchestrate immunity to respiratory virus infection. Immunity 2020; 52:1–18.
62 Petes C, Mintsopoulos V, Finnern RL et al. The effects of CD14 and IL-27 on induction of endotoxin tolerance in human monocytes and macrophages. J Biol Chem 2018; 293:17631–45.
63 McCulloch L, Allan SM, Emsley HC et al. Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. F1000Res 2019; 8:1039.
64 Sabatino JJ, Pröbstel AK, Zamvil SS. B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci 2019; 20:728–45.
65 Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol 2015; 15:149–59.
66 Palm AKE, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front Immunol 2019; 10:1787.
67 Seifert M, Przekopowitz M, Taudien S et al. Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions. Proc Natl Acad Sci 2015; 112:E546–E555.
68 Klehmet J, Harms H, Richter M et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 2009; 158:1184–93.
69 Vogelgesang A, Grunwald U, Langner S et al. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol 2013; 13:88–100.
70 Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol 2013; 13:88–100.
71 Krishnan S, Prise IE, Wemyss K et al. Amphiregulin-producing γδ T cells are vital for safeguarding oral barrier immune homeostasis. Proc Natl Acad Sci USA 2018; 115:10738–43.
72 Ridaaura VK, Bouladoux N, Claesen J et al. Contextual control of skin immunity and inflammation by Corynebacterium. J Exp Med 2018; 215:785–799.
73 Gelderblom M, Gallizzioli M, Ludewig P et al. IL-23 (interleukin-23)–producing conventional dendritic cells control the detrimental IL-17 (interleukin-17) response in stroke. Stroke 2018; 49:155–64.
74 Cibrián D, Sánchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol 2017; 47:946–53.
75 Latchman Y, Wood CR, Chernova T et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2:261–8.
76 Carter LL, Fouser LA, Jussif J et al. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol 2002; 32:634–43.
77 Sathaliyawala T, Kubota M, Yudanin N et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 2013; 38:187–97.
78 Gate D, Saligrama N, Leventhal O, et al. Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 2020; 577:399–404.
79 Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity 2018; 48:202–213.
80 Planas AM, Gómez-Choco M, Urra X et al. Brain-derived antigens in lymphoid tissue of patients with acute stroke. J Immunol 2012; 188:2156–63.
81 Javidi E, Magnus T. Autoimmunity after ischemic stroke and brain injury. Front Immunol 2019; 10:686.
82 Romer C, Engel O, Winek K et al. Blocking stroke-induced immunodeficiency increases CNS antigen-specific autoreactivity but does not worsen functional outcome after experimental stroke. J Neurosci 2015; 35:7777–94.
83 Zhang Y, Wei L, Du Y et al. Association between programed cell death-1 and CD4+ T cell alterations in different phases of ischemic stroke patients. Front Cell Neurosci 2018; 12:1–11.
84 Zhang DP, Yan FL, Xu HQ et al. A decrease of human leucocyte antigen-DR expression on monocytes in peripheral blood predicts stroke-associated infection in critically-ill patients with acute stroke. Eur J Neurol 2009; 16:498–505.
85 Dressel A, Vogelgesang A, Ruhnau J. The expanding phenotype of stroke-induced monocytes: implications for post-stroke infections. Neuroimmunol Neuroinflammation 2014; 1:15.
86 Guillas M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. Immunity 2018; 49:595–613.
87 Villani AC, Satija R, Reynolds G et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 2017; 80:356.
88 See P, Dutertre CA, Chen J et al. Mapping the human DC lineage through the integration of high-dimensional techniques. Science 2017; 80:356.
89 Roquilly A, Braudeau C, Cinotti R et al. Impaired blood dendritic cell numbers and functions after aneurysmal subarachnoid hemorrhage. PLOS ONE 2013; 8:1–10.
90 Dutertre C, Becht E, Irac SE et al. Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells. Immunity 2019; 51:573–89.e8.
91 Meisel A, Meisel C, Harms H et al. Predicting post-stroke infections and outcome with blood-based immune and stress markers. Cerebrovasc Di 2012; 33:580–8.
92 Hernández-Jiménez E, Gutierrez-Fernández M, Cubillos-Zapata C et al. Circulating monocytes exhibit an endotoxin tolerance status after acute ischemic stroke: mitochondrial DNA as a putative explanation for poststroke infections. J Immunol 2017; 198:2038–46.
93 Askenegro MH, Han S-JI, Byrd AL et al. Bone-marrow-resident NK cells prime monocytes for regulatory function during infection. Immunity 2015; 42:1130–42.
94 Netea MG, Joosten LABB, Latz E et al. Trained immunity: a program of innate immune memory in health and disease. Science 2016; 80:52.
95 Courties G, Herisson F, Sager HB et al. Ischemic stroke activates hematopoietic bone marrow stem cells. Circ Res 2015; 116:407–17.
96 Schwarting S, Litwak S, Hao W et al. Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke 2008; 39:2867–75.
97 Massberg S, Schaefer P, Knezevic-Maramica I et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 2007; 131:994–1008.
98 Schloss MJ, Swirski FK, Nahrendorf M. Modifiable cardiovascular risk, hematopoiesis, and innate immunity. Circ Res 2020; 126:1242–59.
Supporting Information

Additional supporting information may be found in the online version of this article at the publisher’s web site:

**Fig. S1.** Immune cell types identified in stroke patients. (A,B) Representative FACS plots showing flow cytometric gating strategy employed to identify myeloid cell subsets (A) and HSPCs (B) in control and stroke patients. Lineage contains CD3, CD19, CD20, CD15, CD56, CD66b.

**Fig. S2.** Composition of the myeloid compartment in patients during the hyper-acute phase of stroke. (A) Population averaged and normalised gene expression of CCR2 in the indicated human monocyte and dendritic cell (DC) subsets obtained from the Human Cell Atlas project. (B-D) Frequencies of granulocytes (B), monocytes and their subsets (C) and DCs (D) amongst live cells in controls (n = 13) and stroke patients (n = 11). (E,F) Correlation plot of cDC1 frequencies with stroke severity (NIHSS) (E) and HLA-DR expression on cDC2s with NIHSS and age (F). Data are presented as bars showing median values and dots representing individual data points. In correlations, the regression line and standard error are shown. Statistical comparisons were performed using a Mann Whitney U test and correlations using Spearman ranked coefficient correlation test.

**Fig. S3.** The T cell compartment in patients during the hyper-acute phase of stroke. (A) Frequencies of CD4+, CD8+, Vδ2+ and other γδ T cells amongst CD3+ T cells in controls (n = 12) and stroke patients (n = 10). (B) Frequencies of naïve, TCM, TEM and TEMRA CD8+ T cell subsets amongst CD8+ T cells in controls (n = 12) and stroke patients (n = 10). (C) Correlation plots of CD69+ naïve and TCM CD4+ cells with stroke severity (NIHSS). Data are presented as bars showing median values and dots representing individual data points. In correlations, the regression line and standard error are shown. Statistical comparisons were performed using a Mann Whitney U test and correlations using Spearman ranked coefficient correlation test.